Viewing Study NCT06077760


Ignite Creation Date: 2025-12-25 @ 2:17 AM
Ignite Modification Date: 2025-12-27 @ 11:02 PM
Study NCT ID: NCT06077760
Status: RECRUITING
Last Update Posted: 2025-12-18
First Post: 2023-10-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module